NSAIDs and cancer
This article was originally published in The Tan Sheet
Executive Summary"Owing to the limited prevention strategies available for breast and ovarian cancers, the potential for commonly used analgesics, such as aspirin and NSAIDs, as chemopreventive agents could have considerable public health benefit," Katherine Crew, Mailman School of Public Health, Columbia University, et al., state in the February Current Opinion in Obstetrics & Gynecology. However, "it is still too early to suggest that the regular use of these drugs could help prevent breast or ovarian cancers [and] it would not be wise to promote regular aspirin or NSAID use for cancer prevention until other health risks from these medications, such as gastric ulcers could be assessed," they state. The article provides a review of studies evaluating the link between aspirin, NSAIDs and cancer. "The majority of case-control studies have shown that the regular use of NSAIDs is associated with a decreased risk of breast cancer," Crew et al. state, noting that the optimal dose, frequency and type of NSAID required for maximum reduction of cancer risk is still unknown...
You may also be interested in...
Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971
It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform with ISO 14971:2019.
Here’s a crosswalk for recently revised international risk management standard ISO 14971 and its 2007 predecessor.
Headed for its second reading in the Florida House after its counterpart passed the Senate on 29 January, HB 113 would expressly preempt local regulation of OTC drugs and cosmetics. According to House analysis documents, “This nullifies the current City of Key West ordinance” banning the sale of sunscreens containing reputed coral-killing UV filters.